abstract |
A chimeric recombinant fusion protein, comprising: (a) a combination of at least two S100A9-binding moieties selected from the group consisting of a human CD33 extracellular domain, a toll-like receptor 4 (TLR4) extracellular domain and a receptor extracellular domain for advanced glycation end products (RAGE); and (b) an immunoglobulin Fc region. |